Professor Stephan Jacob

Back

Professor Stephan Jacob

Villingen (Germany)

Presentations Events

Q&A and panel discussion.

Event: ESC Congress 2022

Topic: Diabetes and the Heart

Session: GLP-1 RAs: more than just glucose-lowering agents

Access

Practical considerations for the use of GLP-1 RAs in the clinic.

Event: ESC Congress 2022

Topic: Diabetes and the Heart

Session: GLP-1 RAs: more than just glucose-lowering agents

Access

What should we do when we are presented with an individual who has CVD and comorbid obesity?

Event: ESC Congress 2021 - The Digital Experience

Topic: Risk Factors and Prevention

Session: Navigating obesity treatment for prevention of CVD

Access

Type 2 Diabetes & CV outcomes: more than Glucose management? Lessons from GLP1-ra trials.

Event: EuroPrevent 2019

Topic: Diabetes and the Heart

Session: The preventive challenge in diabetes & CVD: a multidisciplinary approach.

Access

Discussion - GLP-1 RA in diabetes and cardiovascular disease - What are the key opportunities for cardiology practice

Event: ESC Congress 2018

Topic: Diabetes and the Heart

Session: Outcomes of GLP-1 RA in diabetes and cardiovascular disease - Discussing the key opportunities for cardiology practice

Access

Summary - GLP-1 receptor agonists - The cardiovascular benefits beyond glucose control.

Event: ESC Congress 2018

Topic: Diabetes and the Heart

Session: Outcomes of GLP-1 RA in diabetes and cardiovascular disease - Discussing the key opportunities for cardiology practice

Access

Panel discussion: discussing the benefits in cardiovascular risk, diabetes & heart failure.

Event: ESC Congress 2018

Topic: Diabetes and the Heart

Session: Targeting SGLT2 in clinical cardiology: discussing the benefits in cardiovascular risk, diabetes & heart failure

Access

Changing focus in diabetes: From glucose to cardiovascular risk management.

Event: ESC Congress 2018

Topic: Diabetes and the Heart

Session: Targeting SGLT2 in clinical cardiology: exploring the benefits in cardiovascular risk, diabetes & heart failure (EBAC Accredited)

Access

ESC 365 is supported by

Explore sponsored resources

Professor Stephan Jacob Follow

Contributor content

Q&A and panel discussion.

Practical considerations for the use of GLP-1 RAs in the clinic.

What should we do when we are presented with an individual who has CVD and comorbid obesity?

Type 2 Diabetes & CV outcomes: more than Glucose management? Lessons from GLP1-ra trials.

Discussion - GLP-1 RA in diabetes and cardiovascular disease - What are the key opportunities for cardiology practice

Summary - GLP-1 receptor agonists - The cardiovascular benefits beyond glucose control.

Panel discussion: discussing the benefits in cardiovascular risk, diabetes & heart failure.

Changing focus in diabetes: From glucose to cardiovascular risk management.

ESC 365 is supported by

Professor Stephan Jacob